

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques



- Editorial:
Decade of the Brain 263
- Studies on Cerebellar
Incoordination 264, 275
- Facteurs environnementaux dans
la maladie de Parkinson 286
- Clinical Trials of Clobazam in
Epilepsy 311, 317
- Table of Contents page i

XXVth Canadian Congress of
Neurological Sciences
June 18-22, 1991
Halifax, Nova Scotia

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 17, No. 3

August 1990



To a parkinsonian patient, a little help means a lot.

Adding Parlodel to levodopa can improve symptom control. Because you want to help your patient get more out of life's little pleasures.

Add

PARLODEL[®] 
(bromocriptine mesylate)

Because quality of life is the issue.

 **SANDOZ**

Sandoz Canada Inc.
P.O. Box 385
Dorval, Quebec
H9R 4P5



For brief prescribing information see page xix
information see page xix



Table of Contents

EDITORIAL

Decade of the Brain	263
---------------------------	-----

ORIGINAL ARTICLES

Coordination of a Multi-Joint Movement in Normal Humans and in Patients with Cerebellar Dysfunction <i>W.J. Becker, E. Kunesch and H.-J. Freund</i>	264
Manual Tracking Performance in Patients with Cerebellar Incoordination: Effects of Mechanical Loading <i>Betty-Lynn Morrice, Werner J. Becker, J.A. Hoffer and Robert G. Lee</i>	275
Facteurs environnementaux dans l'étiologie de la maladie de Parkinson <i>J. Zayed, S. Ducic, G. Campanella, J.C. Pansset, P. André, H. Masson and M. Roy</i>	286
Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function <i>Erich Mohr, Irene Litvan, Jill Williams, Paul Fedio and Thomas N. Chase</i>	292
Parkinsonism with Neuroacanthocytosis <i>R.F. Peppard, C.S. Lu, Nai-Shin Chu, P. Teal, W.R.W. Martin and D.B. Calne</i>	298
Lack of Association Between Two Restriction Fragment Length Polymorphisms in the Genes for the Light and Heavy Neurofilament Proteins and Alzheimer's Disease <i>Ginette Lacoste-Royal, Martine Mathieu, Josephine Nalbantoglu, Jean-Pierre Julien, Serge Gauthier and Denis Gauvreau</i>	302
Syncope in Childhood: A Case Control Clinical Study of the Familial Tendency to Faint <i>Peter R. Camfield and Carol S. Camfield</i>	306
The Value of CT Scans for Children with Headaches <i>J.M. Dooley, P.R. Camfield, M. O'Neill and A. Vohra</i>	309
Add-on Trial of Clobazam in Intractable Adult Epilepsy with Plasma Level Correlations <i>A. Guberman, M. Couture, K. Blaschuk and A. Sherwin</i>	311
Clobazam as an Add-on Drug in the Treatment of Refractory Epilepsy of Childhood <i>D.L. Keene, S. Whiting and P. Humphreys</i>	317
Extracranial Repair of Cerebrospinal Fluid Rhinorrhea <i>Ian B. Ross, Austin R.T. Colohan and Martin J. Black</i>	320
Paraneoplastic Encephalomyelitis and Subacute Dysautonomia due to an Occult Atypical Carinoid Tumour of the Lung <i>M. Veilleux, J.P. Bernier and J.B. Lamarche</i>	324
Primary CNS Lymphoma: Lymphomatous Meningitis Presenting as a Cauda Equina Lesion in an AIDS Patient <i>Pavel Klein, Gary Zientek, Scott R. VandenBerg and Eric Lothman</i>	329
Clinical Recovery and Sleep Architecture Degradation <i>Vladimir C. Hachinski, Mortimer Mamelak and John W. Norris</i>	332
Fatal Streptokinase-Induced Intracerebral Haemorrhage in Cerebral Amyloid Angiopathy <i>D.A. Ramsay, J.L. Penswick and D.M. Robertson</i>	336

ABSTRACTS

Abstracts of the Canadian Association of Neuropathologists 1989 Meeting	342
---	-----

CORRESPONDENCE	352
----------------------	-----

NOTES AND ANNOUNCEMENTS	355
-------------------------------	-----

CALENDAR OF EVENTS	356
--------------------------	-----

BOOK REVIEWS	358
--------------------	-----

INSTRUCTIONS TO AUTHORS	vi
-------------------------------	----

ADVERTISERS INDEX	xxvi
-------------------------	------

LEADERSHIP MEANS SOMETIMES GOING IT ALONE

In the field of Evoked Potentials, one company is still leaving footprints in which others can only hope to follow. Nicolet.

Fifteen years ago, Nicolet introduced the first clinical Evoked Potential system. Today, a third generation of the Nicolet Pathfinder™, the Pathfinder™ MEGA, offers an extensive range of hardware and software options to provide more testing power and flexibility than any other system. New capabilities have been added every year. Based on the pioneering performance of the CA1000, the Nicolet Compact Series provides the standard against which other Evoked Potential systems are measured. And for basic auditory testing, the simplicity and ease of use of the Nicolet Audir™ V are unmatched.

Nicolet has more Evoked Potential systems in clinical and research use than any other manufacturer. And it's not even close.

Make tracks with the leader! Call your local Nicolet Representative to find out how Nicolet can meet your electrodiagnostic needs ... better than anyone.

Nicolet

INSTRUMENTS OF DISCOVERY

Nicolet Biomedical

5225-4 Verona Road, Madison, WI 53711, 608-271-3333, 800-356-0007.

Sales and Service Offices Worldwide, Subsidiary Offices:
Belgium, Canada, France, Japan, United Kingdom, and West Germany



Editor/Rédacteur en chef Robert G. Lee *Calgary*
Associate Editors/Rédacteurs associés Yves Lamarre *Montréal* Harvey B. Sarnat *Calgary*
Terry Picton *Ottawa* Bryce Weir *Edmonton*
Founding Editor/Fondateur-rédacteur Robert T. Ross *Winnipeg*
Book Review Editor/Rédacteur de critiques de livres T. Peter Seland *Calgary*
News Editor/Rédacteur (nouvelles) John Norris *Toronto*
Managing Editor/Administratrice adjointe Sally A. Gregg *Calgary*

Editorial Board/Conseil Scientifique

Albert J. Aguayo <i>Montréal</i>	Morton Low <i>Houston</i>
Henry J.M. Barnett <i>London</i>	Thomas J. Murray <i>Halifax</i>
Larry Becker <i>Toronto</i>	Jean Reiher <i>Sherbrooke</i>
Paul Bédard <i>Québec</i>	Leo P. Renaud <i>Montréal</i>
Donald Calne <i>Vancouver</i>	Richard Riopelle <i>Kingston</i>
Pierre Duquette <i>Montréal</i>	Matthew W. Spence <i>Halifax</i>
George Ebers <i>London</i>	Richard Stein <i>Edmonton</i>
John Girvin <i>London</i>	John Stewart <i>Montréal</i>
Richard Leblanc <i>Montréal</i>	Charles Tator <i>Toronto</i>
William J. Logan <i>Toronto</i>	Simon Verret <i>Québec</i>

Publications Committee/Comité de Rédaction

William F. Brown <i>London</i>	Warren Blume <i>London</i>
Terry Myles <i>Calgary</i>	John Tibbles <i>Victoria</i>

The Official Journal of:/La Revue Officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie
President/Président — Richard Riopelle
Secretary-Treasurer/ — O. Suchowersky
Secrétaire-Trésorier

The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique
President/Président — W. Pryse-Phillips
Secretary-Treasurer/ — Michael Jones
Secrétaire-Trésorier

The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie
President/Président — Arthur Hudson
Secretary-Treasurer/ — Renn Holness
Secrétaire-Trésorier

The Canadian Association for Child Neurology
L'Association Canadienne de Neurologie Pédiatrique
President/Président — Peter Humphreys
Secretary-Treasurer/ — Daniel Keene
Secrétaire-Trésorier

The permanent secretariat for the 4 societies and the Canadian Congress of Neurological Sciences is at/
Le secrétariat des 4 associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:
810, 906 - 12 Avenue S.W., Calgary, AB Canada T2R 1K7

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate is \$60 for Canada, \$70 for USA and elsewhere. Residents, Interns, Pre- and Post-Doctoral Students \$30 per annum. Single copies \$18 each. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Courier to: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Telephone (403) 229-9575. COPYRIGHT© 1990 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under second class registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents* — *Clinical Practice and Life Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 60 \$ au Canada et 70 \$US pour les Etats Unis et ailleurs. Internes, résidents, fellows pré et post doctoral: 30 \$ par année. Copie simple: 18 \$ Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, P.O. Box 4220, Station C, Calgary, AB Canada T2T 5N1. Par courrier: 8th Floor, 906 - 12th Avenue S.W., Calgary, AB Canada T2R 1K7. Téléphone (403) 229-9575. DROITS D'AUTEUR© 1990: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous permis de deuxième classe no 3307. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents* — *Clinical Practice et Life Sciences*.

Advertising representative/Représentant de publicité Sally Gregg, Canadian Journal of Neurological Sciences
810, 906 - 12 Ave. S.W., Calgary, AB Canada T2R 1K7 — (403)-229-9575

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0316 - 1671

Tegretol[®]
CR



A Time For Living

The formative years. A time for living, for being part of the team, the band, the crowd. In this time of belonging, performing and excelling, she has no time for limitations and little tolerance for seizures.

When you are initiating therapy **consider TEGRETOL[®] CR (controlled release carbamazepine) and its benefits.**

Effectiveness: Proven seizure control.

Tolerability: Fewer of the peak related CNS side effects associated with conventional TEGRETOL[®] (carbamazepine).^(1,2)

Convenience: The convenient twice daily dosage may make it easier for patients to comply with. No mid-day dose.

For brief prescribing information see page xxi

G-89037




TEGRETOL[®] CR:
A logical choice that helps her get on with living

(iv)

Geigy

Mississauga, Ontario
L5N 2W5



My patients deserve the best - but only once!

Patient Safety

Sometimes there is a difference between the cost of the test and the price the patient must pay. That's a risk I cannot accept. To limit risk and to dispose of my patients' many concerns I use disposable needle electrodes. I avoid taking chances in my patient care, and my patients don't worry as much about needle safety. Dantec disposables secure the results for me and peace of mind for my patients!

Dantec Quality

A needle can be brand new only once. Use it and then dispose of it!

Dantec's new series of needle electrodes are manufactured according to the same high standards as other Dantec products. Their ergonomic design makes them userfriendly. I have confidence in the needle and my patients have confidence in me. Why risk it? Stick with the best!

DANTEC MEDICAL, Inc.
100 Dynamic Drive
Scarborough, Ontario, M1V 5C4
Phone: (416) 298-2091 • Fax: (416) 298-5704

 **DANTEC**
INNOVATIONS IN TUNE WITH MEDICINE

Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in the clinical and basic neurosciences. Manuscripts are considered for publication with the understanding that, except for identified review articles, they have not been published elsewhere except in abstract form and are not under simultaneous consideration by another publication. Manuscripts should be submitted to:

The Editor
Canadian Journal of Neurological Sciences
P.O. Box 4220
Station C
Calgary, Alberta, Canada T2T 5N1

Manuscripts and all illustrations should be submitted in triplicate. Papers will be accepted in English or French. All papers should be accompanied by an abstract or a résumé of approximately 150 words on a separate page, preferably in both languages, although the Journal will provide the translation if requested. All manuscripts should be double spaced throughout, including references and legends for illustrations. Margins of at least 25 mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points will be summarized here. Articles should be subdivided under conventional headings of "introduction", "methods and materials", "results" and "discussion" but other headings and subheadings will be considered if more suitable for a particular manuscript. A title page should identify the title of the article, authors, name of institution(s) from which the work originated, and the address and telephone number of the author to whom communications should be addressed. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support, should be typed on a separate page at the end of the text.

References are to be numbered in the order of citation in the text. Those cited only in tables or in legends for illustrations are numbered in accordance with a sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should be complete including the names of the first three authors followed by "et al" if there are more than three authors, full title, year of publication, volume number, and inclusive pagination for journal articles. Book or chapter references should also include the place of publication and name of the publisher. Examples of correct forms of references follow:

Journals

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263.

Chapter in a book

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254.

Illustrations should be high quality glossy black-and-white photographic prints, preferably 127 x 173 mm (5 x 7"). Original artwork and radiographs should not be submitted. The additional cost of colour illustration must be borne by the author; quotations are available upon request from the Journal office. All figures should be identified on the back with the author's name and figure number. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with the scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations themselves.

Tables should each be on a separate page and be identified with the title or heading. Particular care should be taken in the preparation of tables to ensure that the data are presented in the most clear and precise format. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees Celsius. Other measurements should be reported in the metric system. English language text may use either British or American spelling, but should be consistent throughout.

Review articles on selected topics also are published by the Journal. These are usually invited, but unsolicited reviews will be considered. It is suggested that authors intending to submit reviews contact the Editor in advance.

Letters to the Editor are welcome. These should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

Information aux auteurs

Le journal Canadien des Sciences Neurologiques publie des articles originaux dans les sciences neurologiques, cliniques et fondamentales. Les manuscrits ne sont considérés pour publication qu'à la condition expresse, à l'exception des articles de revue clairement identifiés comme tel, qu'ils n'aient pas été publiés ailleurs, sauf sous forme de résumé et qu'ils ne soient pas sous considération simultanée par un autre journal. Les manuscrits doivent être soumis à:

L'Éditeur
Journal Canadien des Sciences Neurologiques,
P.O. Box 4220,
Station C,
Calgary, Alberta, Canada T2T 5N1

Les manuscrits et toutes les illustrations doivent être soumis en triplicate. Les articles seront acceptés en français ou en anglais. Tous les articles doivent être accompagnés d'un résumé d'environ 150 mots, sur page séparée, préféablement dans les deux langues, quoique le Journal puisse fournir cette traduction sur requête. Les manuscrits doivent être dactylographiés complètement à double interligne y compris les références et les légendes pour illustrations. Des marges d'au moins 25 mm doivent être laissées de tous les côtés.

Pour les conseils plus détaillés sur le style et la présentation du texte, les auteurs doivent se référer au texte intitulé "Règlements uniformes pour les manuscrits soumis aux journaux biomédicaux". On peut obtenir une copie de ce document en écrivant au bureau du Journal, mais en voici les principaux points: Les articles doivent être présentés selon le plan habituel: "Introduction", "Matériel et méthodes", "Résultats" et "Discussion", mais il est possible d'employer d'autres titres ou sous-titres si nécessaire pour un manuscrit en particulier. Sur une page titre séparée on doit identifier le titre de l'article, les auteurs, les institutions d'où origine le travail, ainsi que l'adresse et le numéro de téléphone de l'auteur à qui devront être adressées les communications. Les remerciements, incluant ceux pour l'appui financier, doivent être dactylographiés sur page séparée à la fin du texte. Les références doivent être numérotées dans l'ordre où elles sont citées dans le texte. Celles qui sont citées seulement dans les tableaux ou légendes d'illustrations sont numérotées selon la séquence établie par la première identification dans le texte de ces tableaux ou illustrations particulières. Les titres des journaux doivent être abrégés selon le style utilisé dans Index Medicus. Les références doivent être complètes, incluant le nom des trois premiers auteurs suivis de "et al", s'il y a plus de trois auteurs, le titre complet, l'année de publication, le numéro du volume et les premières et dernières pages de l'article. Les références aux livres et chapitres de livres doivent aussi inclure le lieu de la publication et le nom de la maison d'édition. Les exemples suivants peuvent être utilisés:

Journaux

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263.

Chapitre de livre

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254.


Les **illustrations** doivent être sur papier brillant de haute qualité et imprimées en blanc et noir, préféablement 127 x 173 mm (5 x 7"). Les illustrations et photographies originales ne doivent pas être soumises. Le coût supplémentaire des illustrations en couleur revient entièrement à l'auteur; les coûts détaillés peuvent être obtenus directement au bureau du Journal. Il faut identifier toutes illustrations en inscrivant au dos le nom de l'auteur et le numéro. Toutes lettres ou flèches appliquées aux illustrations pour identifier un aspect particulier doivent être de qualité professionnelle. Les photomicrographies doivent inclure une barre de calibration dont l'échelle est mentionnée dans la légende. Les légendes des illustrations doivent être dactylographiées sur une page séparée de celles-ci.

Les **tableaux** doivent être sur des pages séparées et être identifiés avec titre. On doit prendre un soin particulier dans la préparation de ces tableaux afin d'assurer que les données soient présentées avec le format le plus clair et le plus précis possible. Chaque colonne doit avoir un court titre. Les explications doivent être placées en dessous du tableau et non en sous-titre. Un tableau ne doit pas être soumis sous forme de photographie.

On doit employer le système international d'unités (SI) pour toutes données de laboratoire, même si celles-ci sont originellement présentées dans un autre système. Les températures doivent être citées en degrés Celsius. Les autres données doivent utiliser le système métrique. Les textes en anglais peuvent utiliser l'orthographe anglais ou américain, mais cet usage doit être constant.

Le Journal publie également des **articles de revue** sur des sujets sélectionnés. Ces articles sont généralement sur invitation, mais, à l'occasion, une revue non sollicitée peut être acceptée. Il serait préférable que les auteurs ayant l'intention de soumettre une telle revue contactent d'abord l'Éditeur.

Nous accueillons les **lettres à l'Éditeur**. Celles-ci doivent se limiter à deux pages, double interligne et peuvent contenir une seule illustration et ne doivent citer qu'un maximum de quatre références.



SAFE, SIMPLE AND ACCURATE...THE CAMINO ICP MONITORING SYSTEM

The Camino System changed ICP monitoring forever by eliminating all fluid coupling and with it, the artifacts, flushing, leveling, debubbling and clogging.

All thanks to a very special transducer...one so tiny, accurate and versatile that it can be used for intra-parenchymal, ventricular, subdural and post-craniotomy monitoring. Unlike external, fluid-coupled monitoring systems, the Camino System is a **closed system**. Since it is never rezeroed, it is never opened to the atmosphere.

All Camino monitoring kits permit **direct** ICP monitoring. The Camino transducer is placed

at the catheter tip, so there are no artifacts from leveling, bubbles, etc. This means greater accuracy and less nursing intervention.

Direct ICP monitoring; Safe, simple and accurate - from Camino Laboratories and


Codman
a Johnson & Johnson company

Peterborough, Ontario

Call toll free;

Ontario 1-800-461-7693,

All other provinces 1-800-461-7664



The evolution of migraine prophylaxis takes you to the origin of pain.

Introducing Sibelium. The first calcium antagonist that focuses its activity directly on the brain to help prevent common and classical migraine.¹⁻⁵

Because it acts selectively, Sibelium exerts its effect without the hemodynamic effects of conventional calcium antagonists. Hence, there have been no effects reported on heart rate, blood pressure or cardiac output.^{1,6,7}

Sibelium effectively reduces the frequency and severity of migraine. Reduction in migraines is usually evident in the first 4 weeks of therapy. In general, continued therapy results in further decreases in both frequency and severity of migraine.^{3-6,8-10}

The most common side effect of Sibelium is transient sedation. Some patients may experience a slight weight gain in the first few months of therapy. These side effects rarely require discontinuation of Sibelium.^{1,3-6,8-10}

Sibelium's once-a-day dosage (2 capsules of 5 mg at bedtime) and generally mild side effects^{3-6,8-10} allow the majority of patients (94.9%)¹ to remain on a 6-9 month course of therapy.

As migraine treatment continues to evolve, Sibelium stands alone in offering significant relief from both the frequency and severity of migraines, with a unique selective action.¹

once-a-day
SIBELIUM
flunarizine

The first selective calcium antagonist for migraine prophylaxis.



For brief prescribing information see page xxii



*Trademark



Extinguishing the burning, throbbing, lancinating pain of diabetic neuropathy

New **Axsain**TM
(capsaicin 0.075% cream)

Excellent relief through efficacy

- ◇ 71% of patients treated with Axsain reported significant pain relief¹
- ◇ 38% mean decrease in pain severity¹
- ◇ Noticeable pain relief within two to four weeks when applied three to four times daily

Excellent comfort through selectivity

- ◇ C-fiber selective; does not affect more discriminatory senses such as touch, pressure or vibration
- ◇ Topical, with no known systemic side effects or drug interactions; can easily be used adjunctively



Relief and comfort through efficacy and selectivity

AxsainTM
(capsaicin 0.075% cream)

For brief prescribing information see page xxiv

<https://doi.org/10.1017/S0950268805005335> AXSAIN is a registered trademark published online by Cambridge University Press

(x)

GENDERM
GenDerm Canada Inc.
355 McCaffrey
Montréal, Québec, H4T 1Z7

Tegretol[®]
CR



Le temps de vivre pleinement

Les années de formation, une période à vivre pleinement, à faire partie d'une équipe, d'un groupe, de la bande. Parce que c'est le temps d'appartenir, d'exécuter, d'exceller, les limitations qu'imposent les crises n'ont donc pas leur place.

Lorsque vous instituez un traitement, **pensez au TEGRETOL[®] CR (carbamazépine à libération contrôlée) et aux avantages qu'il offre.**

Efficacité: contrôle des crises démontré.

Tolérabilité: moins d'effets secondaires reliés aux pics causés par le TEGRETOL[®] conventionnel (carbamazépine).^(1,2)

Commodité: posologie à deux prises par jour plus commode et plus facile à observer, la dose du midi étant éliminée.

TEGRETOL[®] CR:

Un choix logique pour l'aider à vivre pleinement.

Geigy

Mississauga, Ontario
LSN 2W5

ELDEPRYL[®] ADJUNCT IN THE MANAGEMENT OF PARKINSON'S DISEASE

(selegiline hydrochloride) (l-deprenyl hydrochloride) TABLETS 5 mg

ACTIONS AND CLINICAL PHARMACOLOGY ELDEPRYL (selegiline hydrochloride, previously known as l-deprenyl hydrochloride), a synthetic selective inhibitor of the MAO-B enzyme when administered at the recommended doses, has been found to be of value as an adjunct to the management of some patients with Parkinson's Disease when administered as add-on therapy to levodopa/carbidopa. The mechanism of action of ELDEPRYL responsible for its action as an adjunct in the symptomatic management of selected Parkinsonian patients is not well understood. Inhibitors of type MAO-B enzyme may be useful by blocking the metabolism of dopamine and by increasing the net amount of dopamine available. It may increase dopaminergic activity by blocking dopamine uptake at the synapses. Two principal metabolites of ELDEPRYL, l-amphetamine and l-metamphetamine (which with l-desmethylselegiline account for 44% of dose administered, as excreted metabolites) could also play a role. They interfere with neuronal uptake. By inhibiting MAO-B enzyme, ELDEPRYL may prevent the generation of free radicals and hydrogen peroxide resulting from oxidation of dopamine. It may also prevent the conversion of MPTP to MPP. Non-selective inhibitors of MAOs which inhibit MAO-A enzymes are not used in the management of Parkinson patients because of side effects, such as hypertension, increase in involuntary movements and toxic delirium. Toxic delirium has also been reported with ELDEPRYL when used as adjunctive therapy to levodopa treatment. **Hypertensive Crisis ("Cheese Reaction").** The MAOs are currently subclassified into two types, A and B, which differ in their substrate specificity and tissue distribution. In humans, intestinal MAO is predominantly MAO-A while most of that in the brain is MAO-B. In the CNS, MAO plays an important role in the catabolism of catecholamines (dopamine, norepinephrine and epinephrine) and serotonin. The MAOs are also important in the catabolism of various exogenous amines found in a variety of foods and drugs. The MAO-A found in the liver and the gastrointestinal tract is thought to provide vital protection from exogenous amines (e.g. tyramine) that have the capacity, if absorbed intact, to cause a "hypertensive crisis", the so-called "cheese reaction" (if large amounts of certain exogenous amines - e.g. from fermented cheese, red wine, herring, over-the-counter cough/cold medications, etc. - gain access to the systemic circulation, they are taken up by adrenergic neurons and displace norepinephrine from storage sites with n membrane bound vesicles. The subsequent release of the displaced norepinephrine causes the rise in systemic blood pressure, etc.). In theory, therefore, patients treated with ELDEPRYL at a dose of 10 mg a day, because gut MAO-A is not inhibited, can take medications containing pharmacologically active amines and consume tyramine-containing foods without risk of uncontrolled hypertension. To date, clinical experience appears to confirm this prediction: hypertensive crises ("cheese reactions") have not been reported in ELDEPRYL treated patients. However, until the pathophysiology of the "hypertensive crisis" is more completely understood, it seems prudent to assume that ELDEPRYL can only be used safely without dietary restrictions at doses where it presumably selectively inhibits MAO-B (e.g. 10 mg/day). Hence, attention to the dose dependent nature of ELDEPRYL's selectivity is critical if it is to be used without elaborate restrictions being placed on diet and concomitant drug use. (See WARNINGS and PRECAUTIONS). **Pharmacokinetics.** Only preliminary information about the details of the pharmacokinetics of ELDEPRYL and its metabolites is available. Data obtained in a study of 12 healthy subjects that was intended to study the effects of ELDEPRYL on the pharmacokinetics of an oral hypoglycemic agent, however, provides some information. Following the oral administration of a single dose of 10 mg of ELDEPRYL to these subjects, serum levels of intact ELDEPRYL were below the limit of detection (less than 10 ng/ml). Three metabolites, N-desmethylselegiline, the major metabolite (mean half-life 2.0 hours), l-amphetamine (mean half-life 17.7 hours) and l-metamphetamine (mean half-life 20.5 hours) were found in serum and urine. Over a period of 48 hours, 45% of the dose administered appeared in the urine as these three metabolites. In an extension of this study intended to examine the effects of steady state conditions, the same subjects were given a 10 mg dose of ELDEPRYL for seven consecutive days. Under these conditions, the mean trough levels were 3.5 ng/ml for l-amphetamine and 8.0 ng/ml for l-metamphetamine, and those for N-desmethylselegiline were below the levels of detection. The rate of MAO-B regeneration following discontinuation of treatment has not been quantitated. It is this rate, dependent upon *de novo* protein synthesis, which seems likely to determine how fast normal MAO-B activity can be restored. **INDICATIONS AND CLINICAL USE** ELDEPRYL (selegiline hydrochloride) may be of value as an adjunct in the management of some patients with Parkinson's Disease. ELDEPRYL is not indicated as a first line treatment of Parkinson patients but may be of value as add-on therapy. Short term benefits from the drug are frequently lost in the longer run. **CONTRAINDICATIONS** ELDEPRYL (selegiline hydrochloride) is contraindicated in: Patients with known hypersensitivity to this drug. Active peptic ulcer, extrapyramidal disorders such as excessive tremor or tardive dyskinesia, (or in patients with) severe psychosis or profound dementia. ELDEPRYL should not be used at daily doses exceeding those recommended (10 mg/day) because of the risks associated with non-selective inhibition of MAO (see CLINICAL PHARMACOLOGY). The selectivity of ELDEPRYL for MAO-B may not be absolute even at the recommended daily dose of 10 mg/day and selectivity is further diminished with increasing daily doses. The precise dose at which ELDEPRYL becomes a non-selective inhibitor of all MAO is unknown. Doses in the range of 30 to 40 mg a day are known to be non-selective. Because of reports of fatal interactions, MAO inhibitors are ordinarily contraindicated for use with meperidine. This warning is often extended to other opioids. Because the mechanism of interaction between MAO inhibitors and meperidine is unknown, it seems prudent, in general, to avoid this combination. **PRECAUTIONS General.** Some patients given ELDEPRYL (selegiline hydrochloride) may experience an exacerbation of levodopa associated side effects, presumably due to the increased amounts of dopamine reacting with super-sensitive post-synaptic receptors. These effects may often be mitigated by reducing the dose of levodopa/carbidopa by approximately 10 to 30%. The decision to prescribe ELDEPRYL should take into consideration that the MAO system of enzymes is complex and incompletely understood and there is only a limited amount of carefully documented clinical experience with ELDEPRYL. Consequently the full spectrum of possible responses to ELDEPRYL may not have been observed in pre-marketing evaluation of the drug. It is advisable, therefore, to observe the patients closely for atypical responses. **Warning to Patients.** Patients should be advised of the possible need to reduce levodopa/carbidopa dosage after the initiation of ELDEPRYL therapy. The patients (or their families if the patient is incompetent) should be advised not to exceed the recommended daily dose of 10 mg. The risk of using higher daily doses of ELDEPRYL should be explained, and a brief description of the "hypertensive crisis" ("cheese reaction") provided. While hypertensive reactions with ELDEPRYL have not been reported, documented experience is limited. Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with MAO inhibitors induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced. **Laboratory Tests.** No specific laboratory tests are deemed essential for the management of patients on ELDEPRYL. Transient or continuing abnormalities with tendency for elevated values in liver function tests have been described in long term therapy. Although serious hepatic toxicity has not been observed, caution is recommended in patients with a history of hepatic dysfunction. Periodic routine evaluation of all patients is however appropriate. **Drug Interactions.** Other than the possible exacerbation of side effects in patients receiving levodopa/carbidopa therapy, no interactions attributed to the combined use of ELDEPRYL and other drugs have been reported. Because the database of documented clinical experience is limited, the level of reassurance provided by this lack of adverse reporting is uncertain. **Carcinogenesis** Studies to evaluate the carcinogenic potential of ELDEPRYL have not been completed. **Use during Pregnancy.** Insufficient animal reproduction studies with ELDEPRYL have been done to conclude that ELDEPRYL poses no teratogenic potential. However, one rat study carried out at doses as much as 180 fold the recommended human dose revealed no evidence of a teratogenic effect. It is not known whether ELDEPRYL can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ELDEPRYL should be given to a pregnant woman only if clearly needed, and the benefit versus risk must be evaluated carefully. It is not known whether ELDEPRYL is excreted in human milk. Because many drugs are excreted in human milk, consideration should be given to discontinuing the use of all but absolutely essential drug treatments in nursing women. **Pediatric Use.** The effects of ELDEPRYL in children have not been evaluated. **ADVERSE REACTIONS Introduction.** THE SIDE EFFECTS OF ELDEPRYL (selegiline HCl) ARE USUALLY THOSE ASSOCIATED WITH DOPAMINERGIC EXCESS. THE DRUG MAY POTENTIATE THE SIDE EFFECTS OF LEVODOPA/CARBIDOPA. THEREFORE ADJUSTMENT OF DRUG DOSAGES MAY BE REQUIRED. ONE OF THE MOST SERIOUS ADVERSE REACTIONS REPORTED WITH SOME FREQUENCY WITH ELDEPRYL USED AS AN ADJUNCT TO LEVODOPA/CARBIDOPA THERAPY ARE HALLUCINATIONS/CONFUSION, PARTICULARLY VISUAL HALLUCINATIONS. Although a cause and effect relationship has not been established, a tendency to a progressive rise in several liver enzymes has been reported after long term therapy. The number of patients investigated in controlled clinical trials is limited, and therefore the kind of information required to provide an estimate of incidence of adverse reactions is not available. In prospective clinical trials, the following adverse effects, in decreasing order of frequency, led to discontinuation of treatment with ELDEPRYL: nausea, hallucinations, confusion, depression, loss of balance, insomnia, orthostatic hypotension, increased akinesic/involuntary movements, agitation, arrhythmia, bradykinesia,

chorea, delusions, hypertension, new or increased angina pectoris and syncope. Events reported only once as a cause of discontinuation are ankle edema, anxiety, burning lips/mouth, constipation, drowsiness/lethargy, dystonia, excess perspiration, increased freezing, gastrointestinal bleeding, hair loss, increasing tremor, nervousness, weakness and weight loss. In controlled clinical trials involving a very limited number of patients (N = 49 receiving ELDEPRYL, N = 50 receiving placebo) the following adverse reactions were reported (incidences are devoid of practical statistical significance).

ADVERSE EVENT	INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS IN CLINICAL TRIAL	
	ELDEPRYL	PLACEBO
Nausea	10	3
Dizziness/Lightheaded/ Famling	7	1
Abdominal pain	4	2
Confusion	3	0
Hallucinations	3	1
Dry mouth	3	1
Vivid dreams	2	0
Dyskinesias	2	5
Headache	2	1
Ache, generalized	1	0
Anxiety/tension	1	1
Anemia	0	1
Diarrhea	1	0
Hair loss	0	1
Insomnia	1	1
Lethargy	1	0
Leg pain	1	0
Low back pain	1	0
Malaise	0	1
Palpitations	1	0
Urinary retention	1	0
Weight loss	1	0

The following is a list of all adverse reactions reported classified by body system: **Central Nervous System, Motor/Coordination/Extrapyramidal:** increased tremor, chorea, loss of balance, restlessness, blepharospasm, increased bradykinesia, facial grimace, falling down, heavy leg, muscle twitch, myoclonic jerks, stiff neck, tardive dyskinesia, dystonic symptoms, dyskinesia, involuntary movements, freezing, festination, increased apraxia, muscle cramps. **Mental Status/Behavioural/Psychiatric:** hallucinations, dizziness, confusion, anxiety depression, drowsiness, behavior/mood change, dreams/nightmares, tiredness, delusions, disorientation, light-headedness, impaired memory, increased energy, transient high, hollow feeling, lethargy, malaise, apathy, overstimulation, vertigo, personality change, sleep disturbance, restlessness, weakness, transient irritability. **Pain/Altered Sensation:** headache, back pain, leg pain, lumbago, migraine, supraorbital pain, throat burning, generalized ache, chills, numbness of toes/fingers, taste disturbance. **Autonomic Nervous System.** Dry mouth, blurred vision, sexual dysfunction. **Cardio-vascular.** Orthostatic hypotension, hypertension, arrhythmia, palpitations, new or increased angina pectoris, hypotension, tachycardia, peripheral edema, sinus bradycardia, syncope. **Gastrointestinal.** Nausea/vomiting, constipation, weight loss, anorexia, poor appetite, dysphagia, diarrhea, heartburn, rectal bleeding, bruxism. **Genitourinary/Gynecologic/Endocrine.** Slow urination, transient anorgasmia, nocturia, prostatic hypertrophy, urinary hesitancy, urinary retention, decreased penile sensation, urinary frequency. **Skin and Appendages.** Increased sweating, diaphoresis, facial hair, hair loss, hematoma, rash, photosensitivity. **Miscellaneous.** Asthma, diplopia, shortness of breath, speech affected. **SYMPTOMS AND TREATMENT OF OVERDOSE** No specific information is available about clinically significant overdoses with ELDEPRYL (selegiline HCl). However, experience gained during the development of ELDEPRYL reveals that some individuals exposed to doses of 600 mg/day of ELDEPRYL, suffered severe hypertension and psychomotor agitation. Since the selective inhibition of MAO-B by ELDEPRYL is achieved only at doses recommended for the treatment of Parkinson's Disease (i.e. 10 mg per day), overdoses are likely to cause significant inhibition of both MAO-A and MAO-B. Consequently, the signs and symptoms of overdose may resemble those observed with marketed non-selective MAO inhibitors (e.g. tranylcypromine, isocarboxazide, and phenelzine). Characteristically, signs and symptoms of overdose with non-selective MAO inhibitors may not appear immediately. Delays of up to 12 hours between ingestion of the drug and the appearance of signs may occur. Importantly, the peak intensity of the syndrome may not be reached for upwards of a day following the overdose. Death has been reported following overdose with non-selective MAO inhibitors. Therefore, immediate hospitalization, with continuous patient observation and monitoring is strongly recommended. The clinical picture of MAO inhibitor overdose varies considerably. Its severity may be a function of the amount of drug consumed. The central nervous system and cardiovascular systems are prominently involved. Signs and symptoms of overdose may include, alone or in combination, any of the following: dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, tremor, convulsions, and coma rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperreflexia, diaphoresis, and cool, clammy skin. Treatment of overdose with non-selective MAO inhibitors is symptomatic and supportive. Induction of emesis or gastric lavage with installation of charcoal slurry may be helpful in early poisoning, provided the airway has been protected against aspiration. Signs and symptoms of central nervous system stimulation, including convulsions, should be treated with diazepam, given slowly intravenously. Phenothiazine derivatives and central nervous system stimulants should be avoided. Hypotension and vascular collapse should be treated with intravenous fluids and, if necessary, blood pressure titration with an intravenous infusion of a dilute pressor agent. It should be noted that adrenergic agents may produce a markedly increased pressor response. Respiration should be supported by appropriate measures, including management of the airway, use of supplemental oxygen and mechanically supported ventilatory assistance, as required. Body temperature should be monitored closely. Intensive management of hyperreflexia may be required. Maintenance of fluid and electrolyte balance is essential. **DOSE AND ADMINISTRATION** The recommended dosage of ELDEPRYL (selegiline HCl) as an adjunct in the management of patients with Parkinson's Disease is 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. Doses higher than 10 mg/day should not be used. There is no evidence that additional benefit will be obtained from the administration of higher doses. The dose of 10 mg/day results in an almost complete selective inhibition of MAO-B enzyme. The inhibitory action of ELDEPRYL is irreversible; the duration of drug effect depends on enzyme regeneration. Higher doses will result in a loss of selectivity of ELDEPRYL towards MAO-B with an increase in the inhibition of type MAO-A. Moreover, there is an increased risk of adverse reactions with higher doses as well as an increased risk of the "cheese reaction" with its hypertensive response. When ELDEPRYL adjunctive therapy is added to the existing levodopa/carbidopa therapeutic regime, a reduction, usually of 10 to 30% in the dose of levodopa/carbidopa (in some instances a reduction of dose of ELDEPRYL to 5 mg/day) may be required during the period of adjustment of therapy or in case of exacerbation of adverse effects. **AVAILABILITY** ELDEPRYL (selegiline HCl) 5 mg tablets, available in bottles of 60 tablets. Each almost white, flat tablet, with one face engraved with "JUL", contains 5 mg of the l-isomer of selegiline HCl (formerly l-deprenyl HCl). The inactive ingredients are Lactose, Starch, Povidone, Magnesium Stearate, and Talc. Product Monograph available to physicians and pharmacists upon request.

REFERENCES: 1. Langston JW. Parkinson's disease: current view. *AM FAM PHYSICIAN* 1987; Mar; 35(3):201-6. 2. Telser JW, Langston J.W. The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease. *SCIENCE* 1989; VOL 245:519-522. 3. Yahr MD. Deprenyl and Parkinsonism. *J NEURAL TRANSM (SUPPL)* 1987; 25:5-12. 4. Poewe W, Gerstenbrand F, Ransmayr G. Experience with selegiline in the treatment of Parkinson's disease. *J NEURAL TRANSM (SUPPL)* 1987; 25:131-5. 5. Birkenmayer W, Knoll J, Riederer P, Youdim MB, Haas V, Marlin J. Increased life expectancy resulting from addition of deprenyl to Madopar treatment in Parkinson's disease: a longterm study. *J NEURAL TRANSM* 1985; 64(2):113-27. 6. Birkenmayer W. Deprenyl (selegiline) in the treatment of Parkinson's disease. *ACTA NEUROL SCAND (SUPPL)* 1983; 95:103-5. 7. Csantka E, Tarczy M. Selegiline in the early and late phases of Parkinson's disease. *J NEURAL TRANSM (SUPPL)* 1987; 25:105-13. 8. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. *ACTA NEUROL SCAND (SUPPL)* 1983; 95:57-80. 9. Presthus J, Berstad J, Lien K. Selegiline (deprenyl) and low-dose levodopa treatment of Parkinson's disease: A double-blind crossover trial. *ACTA NEUROL SCAND* 1987; Sep; 76(3):200-3. 10. Presthus J, Hajba A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. *ACTA NEUROL SCAND (SUPPL)* 1983; 95:127-33. 11. Rinne UK. Deprenyl as an adjunct to levodopa in the treatment of Parkinson's disease. *J NEURAL TRANSM (SUPPL)* 1987; 25:149-55. 12. Birkenmayer W, Riederer P. Deprenyl Prolongs the Therapeutic Efficacy of Combined L-DOPA in Parkinson's Disease. *ADV NEUROL* 1984; 40:475-81.

DEPRENYL RESEARCH LIMITED
Deprenyl Research Limited, 378 Roncesvalles Avenue, Toronto, Ontario M6R 2M7



PARKINSON'S

New Age



ELDEPRYL[®]

selegiline hydrochloride

Adjunct In The Management of
Parkinson's Disease

ELDEPRYL can

- Reduce overall disability
- Renew response to levodopa therapy
- Reduce levodopa requirements
- Reduce levodopa-associated side effects
- Extend the therapeutic horizon of levodopa

With a Simple Dosage Schedule...

10 mg ELDEPRYL per day

And An Excellent Safety Profile

 **DEPRENYL**
TEVA PHARMACEUTICALS LTD.

PAAB
CCPP

(xiii)

For relief from the searing pain of herpes zoster.

The indescribable pain associated with herpes zoster is enough to drive some sufferers to suicide.¹ As a doctor, you've had to stand by helplessly because there has been little you could offer as relief.

Until now.

Current evidence suggests that capsaicin renders the skin insensitive to pain by depleting

and preventing reaccumulation of substance P in peripheral sensory neurons.

Zostrix[®] cream offers temporary relief of the neuralgia associated with and following episodes of herpes zoster infections. It is non-addictive, non-psychoactive and does not interact with systemic medications commonly prescribed for geriatric patients.

For optimal response, patient compliance to physician-directed therapy is vital.

Product monograph and case reports available from GenDerm Canada.

For immediate information call the GenDerm "pain hotline" collect: (514) 738-1808.

A standard of therapy for
postherpetic neuralgia

For brief prescribing
information see page xxiv



GENDERM

GenDerm Canada Inc.
355 McCaffrey
Montréal, Québec H4T 1Z7
® Registered trademark.

1. The Practice of Dermatology 1988
Richard L. Dobson, M.D.
Donald C. Abele, M.D.



Do EP And EMG...



Without A Computer Degree.

You don't have to be a keyboard expert to operate your EP/EMG system. The Nihon Kohden Neuropack Four and Neuropack-Four mini operate at the touch of a button. (Of course, full computer interaction is available, if desired, through the standard RS-232C interface.) Operation is so simple you can concentrate on the patient rather than the system. And it's fast. NK's Neuropack systems are testing before other systems are online.

Another reason so many professionals are choosing Nihon Kohden is the exceptional performance in both EP and EMG modes on the same instrument, *without compromising either function*. Previously, this kind of performance was only available on instruments costing thousands of dollars more.

Ease-of-use, outstanding performance and cost-effectiveness have made Nihon Kohden the world leader in EEG. Now, these same benefits are yours for EP and EMG.


Get full details on Nihon Kohden Neuropack Four and Neuropack-Four mini systems today. You'll find they combine the simplicity, quality and capabilities you want with the features you need. Features such as high-speed thermal array printer, floppy disk drive for patient data storage, dual time base analysis and integrated stimulators.

Call now to (800) 325-0283, (800) 423-2078 in California or (800) 443-2406 in Canada. Or write Nihon Kohden America, Inc., 17112 Armstrong Avenue, Irvine, CA 92714. FAX: (714) 250-3210.



International Office: Nihon Kohden Corp., 31-4, Nishiochiai 1-chome, Shinjuku-ku, Tokyo 161, Japan.

NEW WAVE



Rivotril[®]
CLONAZEPAM ANTICONVULSANT



A leader in CNS research
Hoffmann-La Roche Limited
Etobicoke, Ontario M9C 5J4
© Registered Trade Mark

For brief prescribing
information see page xxiv

14190

24

00